Business Wire (Sat, 15-Aug 7:07 AM ET)
PRNewswire (Mon, 10-Aug 8:31 AM ET)
Market Chameleon (Mon, 29-Jun 3:07 AM ET)
Market Chameleon (Tue, 3-Mar 4:25 AM ET)
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Theravance Biopharma - trades on the NASDAQ stock market under the symbol TBPH.
As of October 30, 2026, TBPH stock price was flat at $17.03 with million shares trading.
TBPH has a beta of 0.72, meaning it tends to be less sensitive to market movements. TBPH has a correlation of 0.04 to the broad based SPY ETF.
TBPH has a market cap of $884.18 million. This is considered a Small Cap stock.
Last quarter Theravance Biopharma - reported $21 million in Revenue and $.18 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.10.
In the last 3 years, TBPH traded as high as $21.03 and as low as $7.44.
TBPH has outperformed the market in the last year with a price return of +20.2% while the SPY ETF gained +11.3%. However, in the short term, TBPH had mixed performance relative to the market. It has underperformed in the last 3 months, returning +1.1% vs +4.1% return in SPY. But in the last 2 weeks, TBPH shares have fared better than the market returning 0.0% compared to SPY -1.8%.
TBPH support price is $17.03 and resistance is $17.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TBPH shares will trade within this expected range on the day.